209 related articles for article (PubMed ID: 25854528)
21. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
22. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).
Abshire TC; Federici AB; Alvárez MT; Bowen J; Carcao MD; Cox Gill J; Key NS; Kouides PA; Kurnik K; Lail AE; Leebeek FW; Makris M; Mannucci PM; Winikoff R; Berntorp E;
Haemophilia; 2013 Jan; 19(1):76-81. PubMed ID: 22823000
[TBL] [Abstract][Full Text] [Related]
24. Analysis of current perioperative management with Haemate
Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
26. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
Tosetto A; Badiee Z; Baghaipour MR; Baronciani L; Battle J; Berntorp E; Bodó I; Budde U; Castaman G; Eikenboom JCJ; Eshghi P; Ettorre C; Goodeve A; Goudemand J; Hay CRM; Hoorfar H; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Mazzucconi MG; Morfini M; Oldenburg J; Peake I; Parra Lòpez R; Peyvandi F; Schneppenheim R; Tiede A; Toogeh G; Trossaert M; Zekavat O; Zetterberg EMK; Federici AB
J Thromb Haemost; 2020 Sep; 18(9):2145-2154. PubMed ID: 32379400
[TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
28. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
[TBL] [Abstract][Full Text] [Related]
29. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
30. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
31. von Willebrand disease: a clinical and laboratory study of sixty-five patients.
Chen YC; Yang L; Cheng SN; Hu SH; Chao TY
Ann Hematol; 2011 Oct; 90(10):1183-90. PubMed ID: 21643680
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
33. Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study.
Vangenechten I; Smejkal P; Zapletal O; Michiels JJ; Berneman Z; Zavrelova J; Blatný J; Penka M; Gadisseur A
Thromb Haemost; 2019 Apr; 119(4):594-605. PubMed ID: 30722078
[TBL] [Abstract][Full Text] [Related]
34. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.
Goudemand J; Bridey F; Claeyssens S; Itzhar-Baïkian N; Harroche A; Desprez D; Négrier C; Chamouni P; Chambost H; Henriet C; Susen S; Borel-Derlon A
J Thromb Haemost; 2020 Aug; 18(8):1922-1933. PubMed ID: 32445594
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of hFVIII/VWF concentrate (Voncento
Rugeri L; d'Oiron R; Harroche A; Proulle V; Mourey G; De Raucourt E; Desprez D; Baikian NI; Petesch BP; Borel-Derlon A; Combe S; Frotscher B; Hassoun A; Catovic H; Bracquart D; Trossaërt M
Blood Transfus; 2021 Mar; 19(2):152-157. PubMed ID: 33263522
[TBL] [Abstract][Full Text] [Related]
36. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
Holm E; Abshire TC; Bowen J; Álvarez MT; Bolton-Maggs P; Carcao M; Federici AB; Gill JC; Halimeh S; Kempton C; Key NS; Kouides P; Lail A; Landorph A; Leebeek F; Makris M; Mannucci P; Mauser-Bunschoten EP; Nugent D; Valentino LA; Winikoff R; Berntorp E
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):383-8. PubMed ID: 25688461
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of slightly reduced von Willebrand factor activity.
Bykowska K; Ceglarek B
Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
[TBL] [Abstract][Full Text] [Related]
38. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
[TBL] [Abstract][Full Text] [Related]
40. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study.
Xu Y; Deforest M; Grabell J; Hopman W; James P
Haemophilia; 2017 Jan; 23(1):115-121. PubMed ID: 27611464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
